Biotech Ventures

The biotech and techbio venture landscape is experiencing a recalibration. After the boom years of early-stage enthusiasm and inflated valuations, the sector is entering a more selective and metrics-driven phase. Yet innovation persists, and some of the most technically ambitious platforms are quietly building in this tighter capital environment.

In this section, we track the companies at the intersection of life sciences and advanced technology, from AI-native drug discovery startups to synthetic biology ventures, novel modality players, and next-gen infrastructure platforms. Whether it's a $4.7 million seed round for a startup addressing clinical trial enrollment, a $235 million growth-stage financing to build an autonomous lab, or recent initial public offerings (IPOs) in biotech, these are the stories shaping the future pipeline.

Here we report on venture funding rounds, public listings, M&A moves, platform development, notable collaborations, and other deals — with a focus on startups, scaleups, and emerging public companies that are shaping where the field is heading.

For deeper trend analysis, refer to our Business Intelligence section. For news and insights on activities by large pharmaceutical and CRO players, see Industry Movers. And for coverage of infrastructure and technology advances — including AI models, lab automation, and organoid platforms — see AI in Bio and Next-Gen Tools.